Question | Discussion | References | CME Credit

Case 1: References

  1. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603-14.
    [The following link will open in a new window. PubMed Abstract]
  2. Moyle GJ, Dejesus E, Cahn P, et al. Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected Adults: Results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr. 2005;38:417-25.
    [The following link will open in a new window. PubMed Abstract]
  3. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis. 2002;34:1137-42.
    [The following link will open in a new window. PubMed Abstract]
  4. Clay PG. The abacavir hypersensitivity reaction: A review. Clin Ther. 2002;24:1502-14.
    [The following link will open in a new window. PubMed Abstract]
  5. Symonds W, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther. 2002;24:565-573.
    [The following link will open in a new window. PubMed Abstract]
  6. Mallal S, Nolan D, Will C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727-32.
    [The following link will open in a new window. PubMed Abstract]
  7. Phillips EJ. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis. 2006;43:103-5.
    [The following link will open in a new window. PubMed Abstract]
  8. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006;43:99-102.
    [The following link will open in a new window. PubMed Abstract]
  9. Mallal S, Phillips E, Carosi G, et al; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-79.
    [The following link will open in a new window. PubMed Abstract]
  10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008;1-128.
    [The following link will open in a new window. AIDSinfo - Accessed March 27, 2008]
  11. Keiser P, Nassar N, Skiest D, Andrews C, Yazdani B, White A, Hetherington S. Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction. Int J STD AIDS. 2003;14:478-81.
    [The following link will open in a new window. PubMed Abstract]
  12. Walensky RP, Goldberg JH, Daily JP. Anaphylaxis after rechallenge with abacavir. AIDS. 1999;28:999-1000.
    [The following link will open in a new window. PubMed Abstract]
  13. Frissen PH, de Vries J, Weigel HM, Brinkman K. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity. AIDS. 2001;15:289.
    [The following link will open in a new window. PubMed Abstract]
  14. Loeliger AE, Steel H, McGuirk S, Powell WS, Hetherington SV. The abacavir hypersensitivity reaction and interruptions in therapy. AIDS. 2001;15:1325-6.
    [The following link will open in a new window. PubMed Abstract]
  15. Berenguer J, Padilla B, Estrada V, Martin C, Domingo P, Kindelan JM, Ruiz-Guiardin JM. Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug. AIDS. 2002;16:1299-301.
    [The following link will open in a new window. PubMed Abstract]
  16. Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS. 2002;16:2223-5.
    [The following link will open in a new window. PubMed Abstract]
  17. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005;19:979-81.
    [The following link will open in a new window. PubMed Abstract]
  18. Wit FWNM, Wood R, Horban A, et al. Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. AIDS. 2001;15:2423-9.
    [The following link will open in a new window. PubMed Abstract]

[Back to Case 1 Question | Back to Discussion]

CME Credit | Back to Top